Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •Prior treatment with EGFR tyrosine kinase inhibitors or EGFR targeting agent
• •Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry.
• •Have previously completed or withdrawn from this study or any other study investigating Dasatinib.
• •Pregnant or breastfeeding.
• •Documented central nervous system or leptomeningeal metastasis (brain metastasis) at the time of study entry. Patients with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.
• •Serious concomitant disorder, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the investigator).
• •Uncorrected electrolyte disorder, including potassium \<3.0 mEq/L).
• •Gastrointestinal disorder that in the opinion of the study physician may affect absorption of either erlotinib or dasatinib. This also includes the inability to swallow tablets.
• •Prior major surgery or radiation therapy within 14 days of initiation of treatment
• •Electrocardiogram (ECG) abnormalities indicative of cardiac disease (at the discretion of the investigator).
• •Uncontrolled angina, congestive heart failure or MI within six (6) months
• •Diagnosed or suspected congenital long QT syndrome
• •History of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
• •Prolonged QTc interval on pre-entry electrocardiogram (\> 450 msec)
• •Uncontrolled hypertension.
• •History of significant bleeding disorder unrelated to cancer, including:
• •* Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
• •* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
• •Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes including:
• •* quinidine,
• •* procainamide,
• •* disopyramide,
• •* amiodarone,
• •* sotalol,
• •* ibutilide,
• •* dofetilide erythromycins,
• •* clarithromycin,
• •* chlorpromazine,
• •* haloperidol,
• •* mesoridazine,
• •* thioridazine,
• •* pimozide,
• •* cisapride,
• •* bepridil,
• •* droperidol,
• •* methadone,
• •* arsenic,
• •* chloroquine,
• •* domperidone,
• •* halofantrine,
• •* levomethadyl,
• •* pentamidine,
• •* sparfloxacin; and
• •* lidoflazine.
• •Patients with chronic obstructive pulmonary disease or pleural effusions (malignant or benign) requiring chronic oxygen therapy.